309 related articles for article (PubMed ID: 26856250)
1. The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.
Sacchetti E; Magri C; Minelli A; Valsecchi P; Traversa M; Calza S; Vita A; Gennarelli M
Pharmacogenomics J; 2017 Mar; 17(2):146-154. PubMed ID: 26856250
[TBL] [Abstract][Full Text] [Related]
2. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients.
Maffioletti E; Valsecchi P; Minelli A; Magri C; Bonvicini C; Barlati S; Sacchetti E; Vita A; Gennarelli M
Drug Dev Res; 2020 Sep; 81(6):754-761. PubMed ID: 32462699
[TBL] [Abstract][Full Text] [Related]
3. Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.
Xu Q; Wu X; Li M; Huang H; Minica C; Yi Z; Wang G; Shen L; Xing Q; Shi Y; He L; Qin S
Pharmacogenomics J; 2016 Aug; 16(4):357-65. PubMed ID: 26282453
[TBL] [Abstract][Full Text] [Related]
4. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia.
Fijal BA; Kinon BJ; Kapur S; Stauffer VL; Conley RR; Jamal HH; Kane JM; Witte MM; Houston JP
Pharmacogenomics J; 2009 Oct; 9(5):311-8. PubMed ID: 19451915
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.
Stevenson JM; Reilly JL; Harris MS; Patel SR; Weiden PJ; Prasad KM; Badner JA; Nimgaonkar VL; Keshavan MS; Sweeney JA; Bishop JR
Transl Psychiatry; 2016 Feb; 6(2):e739. PubMed ID: 26905411
[TBL] [Abstract][Full Text] [Related]
6. The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.
Wang L; Fang C; Zhang A; Du J; Yu L; Ma J; Feng G; Xing Q; He L
J Psychopharmacol; 2008 Nov; 22(8):904-9. PubMed ID: 18308786
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches.
Ikeda M; Tomita Y; Mouri A; Koga M; Okochi T; Yoshimura R; Yamanouchi Y; Kinoshita Y; Hashimoto R; Williams HJ; Takeda M; Nakamura J; Nabeshima T; Owen MJ; O'Donovan MC; Honda H; Arinami T; Ozaki N; Iwata N
Biol Psychiatry; 2010 Feb; 67(3):263-9. PubMed ID: 19850283
[TBL] [Abstract][Full Text] [Related]
8. Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India.
Kaur G; Gupta D; Chavan BS; Sinhmar V; Prasad R; Tripathi A; Garg PD; Gupta R; Khurana H; Gautam S; Margoob MA; Aneja J
Asian J Psychiatr; 2017 Oct; 29():174-182. PubMed ID: 28692863
[TBL] [Abstract][Full Text] [Related]
9. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.
Ikeda M; Yamanouchi Y; Kinoshita Y; Kitajima T; Yoshimura R; Hashimoto S; O'Donovan MC; Nakamura J; Ozaki N; Iwata N
Pharmacogenomics; 2008 Oct; 9(10):1437-43. PubMed ID: 18855532
[TBL] [Abstract][Full Text] [Related]
10. Variants of GRM7 as risk factor and response to antipsychotic therapy in schizophrenia.
Liang W; Yu H; Su Y; Lu T; Yan H; Yue W; Zhang D
Transl Psychiatry; 2020 Mar; 10(1):83. PubMed ID: 32127521
[TBL] [Abstract][Full Text] [Related]
11. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study.
Yu H; Yan H; Wang L; Li J; Tan L; Deng W; Chen Q; Yang G; Zhang F; Lu T; Yang J; Li K; Lv L; Tan Q; Zhang H; Xiao X; Li M; Ma X; Yang F; Li L; Wang C; Li T; Zhang D; Yue W;
Lancet Psychiatry; 2018 Apr; 5(4):327-338. PubMed ID: 29503163
[TBL] [Abstract][Full Text] [Related]
12. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis.
Maldonado-Montoro M; Cañadas-Garre M; González-Utrilla A; Plaza-Plaza JC; Calleja-Hernández MŸ
Pharmacol Res; 2016 Sep; 111():264-271. PubMed ID: 27339827
[TBL] [Abstract][Full Text] [Related]
13. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.
Lane HY; Chang YC; Chiu CC; Chen ML; Hsieh MH; Chang WH
Am J Psychiatry; 2002 Sep; 159(9):1593-5. PubMed ID: 12202283
[TBL] [Abstract][Full Text] [Related]
14. Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study.
Ramsey TL; Liu Q; Massey BW; Brennan MD
Schizophr Res; 2013 Sep; 149(1-3):21-5. PubMed ID: 23886675
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.
Bishop JR; Reilly JL; Harris MS; Patel SR; Kittles R; Badner JA; Prasad KM; Nimgaonkar VL; Keshavan MS; Sweeney JA
Psychopharmacology (Berl); 2015 Jan; 232(1):145-54. PubMed ID: 25096017
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample.
Brandl EJ; Tiwari AK; Zai CC; Nurmi EL; Chowdhury NI; Arenovich T; Sanches M; Goncalves VF; Shen JJ; Lieberman JA; Meltzer HY; Kennedy JL; Müller DJ
Pharmacogenomics J; 2016 Aug; 16(4):352-6. PubMed ID: 26323598
[TBL] [Abstract][Full Text] [Related]
18. Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study.
Zhao M; Ma J; Li M; Zhu W; Zhou W; Shen L; Wu H; Zhang N; Wu S; Fu C; Li X; Yang K; Tang T; Shen R; He L; Huai C; Qin S
Transl Psychiatry; 2022 Apr; 12(1):173. PubMed ID: 35484098
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 polymorphisms are associated with effects of risperidone on neurocognitive performance in schizophrenia.
Zeng L; Kang C; Yuan J; Zhang Y; Wei Y; Xu L; Zhou F; Yang J
Schizophr Res; 2017 Oct; 188():50-51. PubMed ID: 28131599
[No Abstract] [Full Text] [Related]
20. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia.
Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Huang CH; Tsai GE
J Clin Psychopharmacol; 2008 Feb; 28(1):64-8. PubMed ID: 18204343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
